Product Name: Memantine Hydrochloride CAS NO:41100-52-1
Chemical & Physical Properties:
Appearance : White powder
Boiling Point:239.8℃ at 760 mmHg
Memantine hydrochloride is a dementia treatment drug developed by the German Merz company. It is a new, low-to-moderate affinity, voltage-dependent, non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. It can block NMDA receptors non-competitively, reduce the excessive excitement of NMDA receptors caused by glutamate, prevent cell apoptosis and improve memory. It is a new generation of drugs to improve cognitive function.
In February 2002, the European Patent Medicines Committee (CPMP) approved it for the treatment of patients with moderate and severe Alzheimer’s disease. It was launched in Germany in August of the same year and was approved by the U.S. Food and Drug Administration on October 17, 2003 ( FDA) approved for the treatment of patients with moderate to severe Alzheimer's disease. Further research shows that memantine hydrochloride is also effective for patients with mild to moderate Alzheimer's disease.
Alzheimer's disease (Alzheimerdisease, AD), also known as senile dementia, is one of the common diseases of the elderly, mainly manifested as memory loss and recognition impairment, and it is a progressive neurodegenerative disease. Currently, cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine hydrochloride are approved for the treatment of Alzheimer's disease.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.